Primary Biliary Cholangitis — Research Summary

Printed from RareWays (rareways.com.au) on 5 April 2026

For general awareness only. Not medical advice. Discuss all care options with your healthcare team.

5 Most Recent Research Articles

1.
Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3.
Lu Wenlong et al. — RNA biology (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41879109/
2.
HPV vaccination intention among unvaccinated international and domestic college students in the U.S.: A cross-sectional survey.
Liu Cheng-Ching et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41528093/
3.
Propagation and scattering of ultrasonic waves in macroscopically anisotropic polycrystalline materials with fiber texture.
Victoria-Giraldo Juan Camilo et al. — Ultrasonics (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41812467/
4.
Lignocellulolytic fungi to tailor hydrophobic microstructures of biochar for efficient and selective removal of diverse emerging contaminants.
Chen Yu et al. — Bioresource technology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41855997/
5.
Longitudinal multi-omics pilot study: Small sample size human model of gut microbiota-mitochondrial metabolic dysregulation in primary biliary cholangitis.
Lou Jing et al. — Microbiological research (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41666519/

Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1.
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Recruiting — Phase 2 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT07063745
2.
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT07213804
3.
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Recruiting — Phase 3 — Novo Nordisk A/S
https://clinicaltrials.gov/study/NCT07253285
4.
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT07227402
5.
Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors
Recruiting — Chinese University of Hong Kong
https://clinicaltrials.gov/study/NCT06549673
6.
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06170788
7.
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT06439277
8.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT06119581
9.
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Recruiting — Phase 3 — Bayer
https://clinicaltrials.gov/study/NCT06452277
10.
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Recruiting — Phase 3 — Olema Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT06016738
11.
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Recruiting — Phase 3 — Mirati Therapeutics Inc.
https://clinicaltrials.gov/study/NCT06875310
12.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting — Phase 3 — Ipsen
https://clinicaltrials.gov/study/NCT06016842
13.
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Recruiting — Phase 3 — Janssen Research & Development, LLC
https://clinicaltrials.gov/study/NCT06750094
14.
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Recruiting — Phase 2 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT07076121
15.
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Recruiting — Phase 1 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT07293351
16.
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Recruiting — Phase 3 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT06646276
17.
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Recruiting — Phase 3 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT07361497
18.
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Recruiting — Phase 3 — Amgen
https://clinicaltrials.gov/study/NCT06117774
19.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
20.
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06074588
21.
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Recruiting — Phase 3 — Pfizer
https://clinicaltrials.gov/study/NCT07144280
22.
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting — Phase 3 — Gilead Sciences
https://clinicaltrials.gov/study/NCT06051617
23.
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT07422480
24.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Recruiting — Phase 3 — Pfizer
https://clinicaltrials.gov/study/NCT06758401
25.
The Dragon PLC Trial (DRAGON-PLC)
Recruiting — Na — Maastricht University
https://clinicaltrials.gov/study/NCT06914648
26.
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Recruiting — Phase 3 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT05949684

Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.

Always verify information with your healthcare team before making any decisions about your care.

ICD K74.3ORPHA:186PBC

Primary Biliary Cholangitis

Primary Biliary Cholangitis is a chronic autoimmune liver disease that slowly destroys the small bile ducts within the liver, leading to bile accumulation, liver damage, and eventually cirrhosis. It predominantly affects women over 40, with a prevalence of approximately 1 in 1,000 in that group. UDCA and obeticholic acid are the main treatments.

↓ Latest research ↓ Clinical trials(138 recruiting)↓ Research library (670 articles)

670

Articles

684

Trials (104 AU)

Updated

5 April 2026

Most Recent Research

Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3.

Lu Wenlong et al.RNA biology31 December 2026

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by autoimmune-mediated destruction of intrahepatic bile ducts. Emerging evidence suggests that circular RNAs (circRNAs) play regulatory roles in autoimmune diseases, but their involvement in PBC remains unclear. This study focused on the hsa_circ_0000711 and its potential mechanism in PBC pathogenesis. The study included 46 PBC patients, 40 healthy controls, and 40 patients with other liver diseases. Human intrahepatic biliary epithelial cells (HiBEpic) were treated with 1 mM glycochenodeoxycholic acid (GCDCA) to establish a PBC cell model. Hsa_circ_0000711 was overexpressed or knocked down using plasmid transfection and siRNA, respectively. Expression levels were analysed by qPCR/Western blot, cell viability by CCK-8, and hsa_circ_0000711-miR-185-5p interaction by luciferase assay. Serum hsa_circ_0000711 levels were significantly higher in PBC patients compared to healthy controls and other liver disease groups (p < 0.0001). GCDCA-treated HiBEpic cells showed increased expression of the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) and nuclear factor of activated T cells 3 (NFATc3), along with decreased cell viability. Overexpression of hsa_circ_0000711 increased PDC-E2 and NFATc3 expression and worsened cellular injury, while its knockdown reversed these effects. The dual luciferase assay confirmed that hsa_circ_0000711 directly binds to miR-185-5p, suppressing its activity and thereby relieving the repression of NFATc3. Hsa_circ_0000711 promotes PBC progression by sponging miR-185-5p and upregulating NFATc3, leading to bile duct epithelial cell injury. These findings highlight its potential as a novel diagnostic biomarker and therapeutic target for PBC.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.